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Abstract
Study objectives: Obstructive sleep apnea hypopnea syndrome (OSAHS) is a sleep-related breathing disorder,
characterized by excessive daytime sleepiness (EDS), paralleled by intermittent collapse of the upper airway. EDS
may be the symptom of OSAHS per se but may also be due to the alteration of central circadian regulation. Irisin is
a putative myokine and has been shown to induce BDNF expression in several sites of the brain. BDNF is a key
factor regulating photic entrainment and consequent circadian alignment and adaptation to the environment.
Therefore, we hypothesized that EDS accompanying OSAHS is reflected by alteration of irisin/BDNF axis.
Methods: Case history, routine laboratory parameters, serum irisin and BDNF levels, polysomnographic measures
and Epworth Sleepiness Scale questionnaire (ESS) were performed in a cohort of OSAHS patients (n = 69). Simple
and then multiple linear regression was used to evaluate data.
Results: We found that EDS reflected by the ESS is associated with higher serum irisin and BDNF levels; β: 1.53; CI:
0.35, 6.15; p = 0.012 and β: 0.014; CI: 0.0.005, 0.023; p = 0.02, respectively. Furthermore, influence of irisin and BDNF
was significant even if the model accounted for their interaction (p = 0.006 for the terms serum irisin, serum BDNF
and their interaction). Furthermore, a concentration-dependent effect of both serum irisin and BDNF was evidenced
with respect to their influence on the ESS.
Conclusions: These results suggest that the irisin-BDNF axis influences subjective daytime sleepiness in OSAS
patients reflected by the ESS. These results further imply the possible disruption of the circadian regulation in
OSAHS. Future interventional studies are needed to confirm this observation.
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Introduction
Obstructive sleep apnea hypopnea syndrome (OSAHS) is
gaining increased attention given its profound societal and
long-term, health related consequences. Reports regarding
its prevalence reflect great variability with some reflecting
a prevalence of 3–7% and 2–5% in men and women,
respectively [1], while others indicating prevalence as high
as 36.5% [2]. OSAHS is a sleep-related breathing disorder
characterized by excessive daytime sleepiness paralleled by
intermittent collapse of upper airway leading to impaired
gas exchange and consequent hypoxemia, events often
terminated by arousal [3, 4]. Airway pathology triggers
sympathetic hyperactivation, inflammation and oxidative
stress paving the way along the continuum of cardio-
metabolic diseases, by contributing to endothelial dysfunc-
tion, insulin resistance, and subsequently results in arterial
hypertension, diabetes mellitus, stroke, myocardial infarc-
tion, heart failure and sudden death [1, 4]. Furthermore,
an independent association between OSAHS and cardio-
vascular as well as all-cause mortality has been shown in
clinical studies [5, 6].Excessive daytime sleepiness per se, a
canonical symptom of OSAHS, leads to more frequent
motor vehicle accidents, diminished work capacity and
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productivity, and is causative in approximately 9.1% of
work-related accidents [2].
Adaptation to the daily fluctuation of light and dark pe-
riods is the most fundamental challenge for an organism,
that basically determines its physiology and behavior. It is
orchestrated by the hierarchically organized circadian
system, the central master clock and peripheral slave clocks
present in most tissues. The master clock resides in the
suprachiasmatic nucleus (SCN). It has an intrinsic pace-
maker activity with its free-running intrinsic circadian
period being longer than the 24 h long environmental
photoperiod [7]. Hence, continuous adjustment (entrain-
ment) is mandatory. The SCN is synchronized to geophys-
ical time mainly through photic signals, and it conveys the
rhythm of the environment to distinct brain areas and
peripheral organs by neuronal and endocrine signals e.g. by
changing sympathetic outflow [8], core body temperature,
melatonin levels, and sleep each adding to the circadian re-
gularity of the organism [9, 10]. Insufficient entrainment of
the master clock causes metabolic syndrome [11], obesity
and diabetes [12], cardiovascular disease [13], depression
[14], cancer [15], and dementia [16, 17]. The SCN is most
readily entrained by light, in a brain-derived neurotrophic
factor (BDNF) dependent manner, rendering BDNF the
gatekeeper, regulating light’s ability to shift the phase of the
master clock. BDNF is a well circumscribed neurotrophin
implicated in maintaining cerebral neuroplasticity [18], by
inducing long-term potentiation and consequent increase
of the strength of synaptic connections [19]. Building on
recent preclinical and clinical observations that BDNF
expression may be induced by irisin, a putative contra
ction-regulated myokine, we have theorized that irisin,
either by crossing the blood-brain-barrier, or by its direct
expression in the hypothalamus is able to increase BDNF
levels in the retinohypothalamic synapse, and hence may
modulate BDNF’s effect on photic entrainment [20].
Research denoting that peripheral signals, e.g. exercise and
fasting, both known to be upstream regulators of irisin
expression, are only able to shift the master clock if light
input is simultaneously present further corroborate this
presumption [21].
Sleep regulation is well conceptualized by the two-
process model of sleep, that posits the continuous inter-
action of oscillating homeostatic processes (growing and
declining sleep debt experienced during wakefulness, and
sleep, respectively) and the circadian pacemaker process,
governed by the master clock. As a result, the phase, ampli-
tude and periodicity of oscillations are entrained in a way
that sleep is properly aligned with the 24-h day-night cycle
[22]. Optimal timing of sleep with regards to the circadian
phase is an important regulatory signal aligning the central
circadian and peripheral tissue specific rhythms [22, 23].
Homeostatic and circadian pacemaker processes interact
albeit are regulated separately.
Circadian misalignment e.g. altered sleep phase, with re-
spect to the circadian environment, and/or altered ampli-
tude of underlying circadian processes leads to diminished
sleep quality and excessive sleepiness, and impaired cogni-
tive performance [24, 25]. Shift in the circadian phase per
se was shown to have a significant effect on subjective
sleepiness, an effect that was more pronounced in younger
(average age 24.5 ± 3.54 years) vs. older (average age 64.0 ±
5.98 years) adults using the forced desynchrony paradigm
[26], hence excessive daytime sleepiness may be indicative
of altered circadian regulation.
Excessive daytime sleepiness is a well characterized
phenomenon of OSAHS, in fact, it was found to be a sig-
nificant and independent predictor of incident cardiovas-
cular events and all-cause mortality in a historical cohort
of 10,149 participants with a follow-up time of 68months
[27]. Moreover, the phenomena of residual sleepiness, e.g.
excessive daytime sleepiness in OSAHS patients treated ef-
fectively with continuous positive airway pressure (CPAP)
therapy, implies that the underlying pathology of excessive
daytime sleepiness is different from that of OSAHS per se.
Conversely, presence oxidative stress and systemic inflam-
mation [1] and a significant association with all-cause and
cardiovascular morbidity and mortality have been reported
as a consequence of residual sleepiness in OSAHS patients
[28, 29]. The need for distinct therapeutic approaches for
managing sleep-related breathing disorders and excessive
daytime sleepiness have also been articulated [1].
Alteration of the circadian rhythm has been implicated
in OSAHS. Blunted daily variability of the expression of
Per1, one of the regulatory genes of the circadian master
clock has been reported along with excessive daytime
sleepiness, mood disturbances and increased incidence of
cardiovascular disease [30, 31]. Conversely, several studies
have provided evidence for the adverse effect of OSAHS
on the circadian secretion of melatonin, considered as one
of the main neural output signals of SCN [24] and a
predictable marker of circadian phase [22]. Synthetized in
the pineal gland, this serotonin-derived hormone has a
short half-life with no depot, rendering circulating mela-
tonin levels highly responsive to light. Melatonin synthesis
is entrained to the ambient light-dark cycle [32], its levels
are low during the day, and begin to rise in evening (in
dim light settings of < 50 Lux) peaking between midnight
and 2 AM [33, 34]. Both endogenous and exogenous mela-
tonin has been shown to induce sleepiness, via their influ-
ence on the circadian component of sleep regulation [35].
Alteration in the function of the master circadian clock
implicated by phase shift or change in the amplitude of
melatonin secretion has been reported in OSAHS patients
[34, 36, 37]. Improper functioning of the master circadian
clock was further suggested by Lemmer and colleagues,
who reported loss of nocturnal peak parallel to the emer-
gence of a prominent peak in melatonin secretion around
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4 AM. Interestingly, 8 weeks of CPAP therapy failed to
alter melatonin levels, blood pressure and heart rate, while
significantly improved deep sleep, slow wave sleep, rapid
eye movement sleep, arousal index, apnea–hypopnea
index, oxygen desaturation index, and the 24 h plasma
norepinephrine levels [37]. Based on these considerations,
we propose that that disruption of circadian rhythm is not
a consequence of the mechanical obstruction of the upper
airways, rather it is a co-evolving pathology further
increasing the disease burden in OSAHS. This notion is
further underscored by the known phenomenon of
residual sleepiness [1].
In the present study we tested the hypothesis that im-
paired circadian rhythm reflected by subjective daytime
sleepiness is influenced by the irisin/BDNF axis, given that
irisin may be able to influence the expression level of
BDNF in the SCN, at the site of photic entrainment, of a
cohort of polysomnography verified OSAHS patients.
Methods
Study design and protocol
The present study was designed in line with the STROBE
statement for cross-sectional studies [38] and was approved
by the Ethical Committee of the University of Debrecen
(DEOEC RKEB/IKEB 3715–2012). Informed consent was
obtained from each participant. The investigation conforms
to the principles outlined in the Declaration of Helsinki.
The current study is based on the analysis of a cohort
of patients who attended the accredited Sleep Medicine
Center of the Department of Neurology (University of
Debrecen) between October 1, 2012 and April 30, 2013
and was diagnosed to have OSAHS. Accreditation was
made by the Hungarian Society for Sleep Medicine in
compliance with European guidelines for the accredit-
ation of Sleep Medicine Centres [39]. Every patient
meeting the diagnostic criteria for OSAHS according to
the relevant Hungarian [40] and concordant inter-
national guidelines [41] were invited to participate, given
they met the inclusion criteria and failed to meet any of
the exclusion criteria. Inclusion criteria were age
between 18 and 80 years and diagnosis of OSAHS at the
time of inclusion. The clinical diagnosis of OSAHS was
made if the number of obstructive events (apneas,
hypopneas + respiratory event related arousals) on poly-
somnography was greater than 5 events/hour, and the
patient reported excessive daytime sleepiness and/or at
least two of the following: repeated nighttime awaken-
ing, unrefreshing sleep, decreased concentration and im-
paired memory, fatigue, repeated gasping or choking
while asleep. Sleep related events were scored according
to standard operational procedures [42] and the manual
of the American Academy of Sleep Medicine [43]. Exclu-
sion criteria included inability to provide informed con-
sent, pregnancy, kidney disease, bronchial asthma or
chronic obstructive pulmonary disease (COPD), inflam-
matory diseases of the face or oral cavity, any systemic
autoimmune disease.
Overall, 70 patients were recruited, data from one
patient was excluded from the analysis due to a highly
significant outlier (serum irisin > 15 ng/mL). Patients were
diagnosed with OSAHS at the time of their recruitment,
thus received no therapy at inclusion for this syndrome.
Each patient underwent a comprehensive sleep evaluation,
neurological examination, polysomnography, and labora-
tory examination, demographic, anthropometric, anam-
nestic data were also acquired. Common carotid artery
intima-media thickness (IMT) was analyzed offline as
described previously [44]. In addition, the Pittsburg Sleep
Quality Questionnaire, the Epworth Sleepiness Scale and
the Beck depression scale were filled out. Patients received
therapy for their co-morbidities as clinically warranted.
Polysomnography
In-laboratory full-night polysomnography was performed
according to the European standard operational procedures
(Fisher 2011) (Philips Alice IV and V, Respiromed, Hungary.
Patients were directed to take their medication as usual on
the night of their sleep study. Patients were mounted with
6 EEG electrodes (F3-M2, C3-M2, C4-M1, O2-M1), 2 EOG
electrodes, 1 submental EMG, ECG (one channel), pulsoxy-
meter, body position sensor, nasal pressure/thermal flow
sensor, snore sensor. Proper, artefact-free functioning of the
recording devices, trouble-shooting was provided by the
continuous oversight of nurses certified in clinical electro-
physiology. Every sleep study was reviewed and interpreted
by a qualified sleep physician. Severity of OSAHS was
quantified by the apnea-hypopnea index (AHI), and the pa-
tient sample was dichotomized for the purpose of descrip-
tive statistics using the cutoff for AHI at < 30/h (mild to
moderate severity vs severe OSAHS) [41]. The following
parameters were included in the statistical analysis: AHI,
oxygen desaturation index (1/h), arousal index (1/ h), cen-
tral apnea index (1/ h), obstructive apnea index (1/ h),,
hypopnea index (1/ h), oxygen saturation below 90% (%).
Blood samples
After an overnight fast blood, samples were drawn in the
morning of the examination. Routine laboratory investiga-
tions were performed according to the standard clinical
practice of the Department of Laboratory Medicine (Uni-
versity of Debrecen), making use of the locally used refer-
ence values. Serum or plasma samples were used for
determining measures descriptive of carbohydrate homeo-
stasis (glucose, insulin, hemoglobin A1c (HgA1c)), lipid
homeostasis (total cholesterol, triglyceride, LDL-cholesterol,
HDL-cholesterol, Lp(a), apoA1, apoB), kidney function
(urea, creatinine), liver function (GOT, GPT, γGT), status
of skeletal muscles (CK, LDH) and systemic inflammation
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(C-reactive protein (CRP)). CRP was dichotomized as high
vs. normal with the cutoff being 4.6mg/L and 5.2mg/L for
female and male patients, respectively. Serum samples used
to determine irisin and BDNF were frozen within 60min
and stored at − 80 °C until further analysis.
Determination of serum irisin and BDNF
BDNF is synthetized in a pre-pro form and may be
released into the circulation as pro-BDNF or mature
BDNF (referred to as BDNF throughout the text) and it
can also cross the blood-brain barrier. The most import-
ant stimulus for the expression and release of BDNF is
excitatory synaptic activity that by releasing glutamate
into the synapse leads to ligand- or voltage-gated
neuronal influx of Na+ and Ca2+ subsequently activating
neuronal transcription factors and inducing BDNF gene
transcription. BDNF is then transported to presynaptic
axon terminals and dendrites and is released upon
glutamate receptor activation [45]. Serum BDNF levels
were measured in accordance with the manufacturer’s
protocol (Sigma-Aldrich, MO, USA). In short, standards
and samples were administered into anti-BDNF mono-
clonal antibody coated 96-well microplates in 100X
dilution and were incubated overnight at 4 °C. Plates
were then washed 4 times and 100 μl of biotinylated
anti-human BDNF antibody was added. The samples
were incubated for 1 h with continuous gentle shaking.
Afterwards, the wells were washed again and 100 μl
HRP-Streptavidin solution was added to the wells for a
45-min long incubation period at room temperature
with gentle shaking. After subsequent washing, 100 μl
TMB One-Step Substrate Reagent was added and incu-
bation was undertaken for 30 min to induce the reaction
leading to colored substrate. The reaction was stopped
by adding the manufacturer-supplied stop solution. The
absorbance was measured at 450 nm with an automatic
microplate reader. The detection limit for BDNF in our
experiment was lower than 80 pg/ml.
Irisin, a highly conservative 12 kDa polypeptide [46], is
formed by proteolysis of the transmembrane protein fibro-
nectin type III domain containing 5 (FNDC5). Expression of
FNDC5 is controlled by peroxisome proliferator-activated
receptor-gamma coactivator protein-1α (PGC1α), a tran-
scriptional co-activator regulating oxidative metabolism in
brown adipose tissue [47]. Expression of both, PGC1α and
FNDC5 may be induced by physical activity and fasting [48,
49]. After proteolytic cleavage of FNDC5, irisin enters the
systemic circulation where it can readily cross the blood-
brain barrier. Albeit most abundant in skeletal muscle,
FNDC5/irisin expression is significant in the adipose tissue
[46], tongue, rectum, and brain while lower levels of irisin
were detected in the kidney, liver and lung [50]. Additional
to the effect currently scrutinized, e.g. inducing BDNF syn-
thesis in the central nervous system, irisin’s most profound
effect is increasing oxygen consumption and thermogenesis
of fat cells [47] by inducing white adipose tissue browning
in various regions [51] via upregulating thermogenic genes
such as uncoupling protein 1 (UCP-1) and PGC1α. Serum
irisin levels were assayed as written in the manufacturer-
supplied instruction manual. We applied a commercially
available ELISA kit (Phoenix Pharmaceuticals, Burlingame,
CA, USA). Briefly, 50 μl of 2X diluted standard or sample,
25 μl primary antibody and 25 μl biotinylated peptide was
added to each well for a 2-h long incubation period at room
temperature. Afterwards, wells were washed four times and
100 μl SA-HRP solution was added for 1 h at room
temperature. After the necessary washing step, 100 μl of
substrate solution was added to each well followed by incu-
bation for 1 h, after which the reaction was stopped with
100 μl/well of 2M HCl. Absorbance was measured subse-
quently at 450 nm. According to the manufacturer’s descrip-
tion, the standard curve of irisin was linear from 1.34 to
29.0 ng/ml, and the detection limit was 1.34 ng/ml. A stand-
ard curve (concentration against optical density) of irisin as
well as BDNF were obtained with each plate. The curves
showed linear relationship within the range of our
measurements.
Questionnaires
Several questionnaires were completed by the study
participants in a supervised administration setting. To as-
sess habitual daytime sleepiness the Epworth Sleepiness
Scale (ESS) [52], one of the most widely used question-
naires, was administered. The ESS is developed to provide
a subjective measure of daytime sleepiness, and contains 8
scenarios in which susceptible patients are likely to doze
off or fall asleep. Patients are asked to assess the probabil-
ity of dozing for each of these situations using the ordinal
scale of 0 to 3 (with 0 and 3 indicating a zero or high
chance of dozing), yielding a minimal and maximal total
score of 0 and 24, respectively indicative of the severity of
excessive sleepiness. The conventional cutoff for excessive
sleepiness is drawn at > 10 points. Previously, significant
correlations were shown between ESS and the objective
measure of sleepiness by the multiple sleep latency test
[53]. The Pittsburgh sleep quality index (PSQI) is a self-
administered questionnaire that contains 19 questions
organized into seven components, each scored on a scale
of 0 to 3 reflecting no difficulty to severe difficulty, re-
spectively [54]. The seven components describe subjective
sleep quality, sleep latency, sleep duration, habitual sleep
efficiency, sleep disturbance, daytime dysfunction and use
of sleeping medication. Component scores are summed to
yield a global score in the range of 0 to 21 point, where 21
indicates severe difficulties in all areas. Component scores
may also be interpreted on their own. Sleep quality is
considered to be impaired if the PSQI global score is > 5.
This reflects severe difficulties in at least two, or moderate
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difficulties in more than three areas. Several of these mea-
sures may reflect the homeostatic aspects of sleep [55]
(e.g. sleep duration, sleep efficiency, sleep disturbance and
use of sleeping medications). Additional to the self-rated
questions the questionnaire contains 5 questions, to be
answered by a roommate. Answers to these questions are
not included in the index.
We used the original Beck Depression Inventory com-
prised of 21 questions descriptive of symptoms and atti-
tudes characteristic of depression. Each question may be
evaluated on a scale of 0 to 3 with respect to intensity [56,
57]. Hungarian versions of these questionnaires were pro-
vided by the Hungarian Society for Sleep Medicine.
Statistical analysis
Normality of continuous variables was checked by the
Shapiro-Wilk test. In case of Gaussian distribution,
Student’s t-test was used for the comparison of two data
sets, if not, Mann-Whitney U test was carried out.
Frequencies were compared with Pearson’s χ2 test.
Demographic, anthropometric, anamnestic, laboratory
and polysomnography data were compared based on the
severity of the OSAHS, using AHI, with cutoff levels of
< 30/h vs ≥ 30/h for mild to moderate severity vs severe
OSAHS, respectively).
For linear regression, parameters showing Gaussian
distribution were used in their raw forms, whereas those
not normally distributed were appropriately transformed
to obtain normal distribution. Accordingly, the parame-
ters were transformed as follows: (log) systolic blood
pressure, (log) weight, 1/body mass index (1/BMI), (log)
abdominal circumference, (log) systolic blood pressure,
log (triglyceride), (log) PSQI, (sqrt) arousal index, (sqrt)
central apnea index, (sqrt) obstructive apnea index,,
(sqrt) hypopnea index, (sqrt) Beck depression score,
(log) triglyceride, (log) HDL-cholesterol.
To identify determinants of Epworth Sleepiness Scale
Score, serum irisin and BDNF levels, simple linear re-
gression was carried out including traditional confound-
ing factors (age, gender), anthropometric parameters
(height, (log) weight, 1/BMI, neck and (log) abdominal
circumference), blood pressure ((log) systolic blood pres-
sure, diastolic blood pressure), intima media thickness,
polysomnographic parameters, laboratory parameters
characteristic of carbohydrate and lipid homeostasis,
(log) PSQI and (sqrt) Beck score. Furthermore, informa-
tion regarding the number of people living in a house-
hold, smoking, benzodiazepine use, presence of diabetes
mellitus, arterial hypertension, coronary artery disease,
cerebrovascular disease, metabolic syndrome (the latter
six parameters dichotomized as yes vs. no) were also
assessed. Polysomnography parameters yielding signifi-
cant regressors were combined into a single parameter
using principal component analysis. Missing data were
omitted. Then, in order to eliminate effects of potential
confounders, multiple linear regression modeling was
performed including both irisin and BDNF levels, and all
significant regressors determined with the simple linear
regression as well as age and gender (as a priori vari-
ables). Variables were introduced into the initial multiple
model simultaneously, then factors not contributing sig-
nificantly to the model were deleted. The final model
contained all variables identified a priori, and (log) PSQI.
In addition, the final model was assessed for the inter-
action of irisin and BDNF. Heteroskedasticity and good-
ness of fit for the model was assessed by Cook-Weisberg
and Ramsey test.
Statistical analysis was performed with Stata 18.0 soft-
ware (Stata Corporation). Values are given as mean ± SD
or median (with the interquartile range: IQR), regression
coefficients are presented with their 95% confidence
interval (CI).
Results
Patients
Data from the 69 patients were analyzed. The average
age was 53.81 ± 10.72 years, and 18 patients were female.
The baseline characteristics of the cohort of OSAHS
patients is summarized in Table 1. Of the 69 patients, 16
patients did not take any medications, 16 patients took
statins, 41 patients took antihypertensives (any of the
following: ACE inhibitor, ARB, beta receptor blocker, Ca
channel antagonist, diuretic, or other), 11 patients took
oral antidiabetics, 19 patients received aspirin, 8 patients
took benzodiazepines and 10 patients used proton pump
inhibitors regularly.
Comparison of patients regarding OSAHS severity
The two strata of our OSAHS cohort, dichotomized by
AHI (cutoff at < 30/h for low to moderate severity) was
homogenous with respect to basic demographic data
(age and gender distribution) and most parameters
(Table 2). However, patients suffering from severe
OSAHS had higher prevalence of arterial hypertension,
were more obese indicated by significantly higher
weight, BMI, larger neck and abdominal circumference.
These patients had a less favorable cardiometabolic risk
profile indicated by significantly higher IMT, serum glu-
cose and HbA1c, triglyceride Lp(a) and Apo-A1 levels,
and lower HDL-cholesterol level. Higher CRP levels and
arterial hypertension were also more prevalent in this
subset of patients. Naturally polysomnography measures
were significantly worse in the subset of patients with se-
vere OSAHS. Furthermore, higher proportion of patients
suffered from daytime sleepiness as indicated by the ESS
in this patient subset (Table 2). Sleep quality and depres-
sion characterized by the PSQI and Beck Depression
Inventory showed no significant difference.
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Associations between Epworth sleepiness score, serum
irisin and BDNF levels
Upon assessing the linear relationship between ESS and
serum irisin levels, we found that their association is on
the verge of statistical significance (p = 0.051), and no
significant association was seen between ESS and serum
BDNF levels (β = 0.008 (− 0.0023; 0.017, p = 0.129). If the
influence of the interaction between serum irisin and
BDNF were assessed, the results were yet again close to
statistical significance (p = 0.055). Significant regressors
of irisin included (log) weight, and (log) triglyceride,
while serum BDNF showed a significant association with
the number of people living in the patient’s household.
ESS showed significant relationships with gender, num-
ber of people living in the same household, several poly-
somnography parameters, measures reflective of obesity,
(sqrt) Beck depression score and (log) PSQI (Table 3).
This relationship between ESS and the two independ-
ent variables of interest, irisin and BDNF showed strong
significant association in the final multiple regression
model (βirisin: 1.53; CI: 3.55, 2.70; p = 0.012; βBDNF: 0.014;
CI: 0.005, 0.023; p = 0.002) that contained a priori determi-
nants and (log) PSQI. Furthermore, significant interaction
between serum irisin and BDNF levels (Table 4) were iden-
tified by the final model. The models not containing and
containing the interaction between the two explanatory
variables of interest were significant (p < 0.001 for both
models). The Cook-Weisberg test showed no heteroskedas-
ticity for either model (p = 0.08 and p = 0.08, respectively).
The Ramsey test showed good fit for both models (p = 0.42;
p = 0.46, respectively). Furthermore, good fit was also
reflected by the locally weighted scatterplot smoothing
(model devoid of the interaction term) (Fig. 1) and also by
visual comparison of the three dimensional plots (axis x, y
and z presenting serum irisin, BDNF levels and ESS, re-
spectively) for the original data set and that fitted to the
data yielded by our model (containing the interaction term)
(Fig. 2). When plotting the final model addressing the inter-
action between irisin and BDNF, it is interesting to note
that significant changes in the ESS are experienced if serum
irisin level changed by 1 ng/mL, given the serum level of
BDNF is within the range of ~ 280 to 470 ng/mL (Fig. 3a).
Vice versa, ESS shows a significant increase in response to
1 ng/mL increase of BDNF if serum irisin levels are within
the range of ~ 6.1 to 8.1 ng/mL (Fig. 3b). The final multiple
linear regression model (built for the ESS) contained only
(log) PSQI additional to the a priori identified parameters.
The model showed that sleep quality is significantly associ-
ated with daytime drowsiness experienced by OSAHS pa-
tients (β: 7.01; CI: 0.85, 13.35; p = 0.026) (this relationship
was significant whether or not the interaction term was in-
cluded in the model).
Discussion
The main finding of our study is that circadian mis-
alignment indicated by excessive daytime sleepiness
(characterized by the ESS) has a strong positive linear
relationship with serum irisin and BDNF levels in a
multiple linear regression model that corrects for age,
gender and the only other significant regressor, (log)
PSQI. Furthermore, we identified an interaction be-
tween serum irisin and BDNF levels with respect to
their effect on ESS, suggestive of a
concentration-response relationship. Our findings sug-
gest that the effect of irisin on BDNF and subsequently
on ESS follows the kinetics of the Hill equation [58].
Accordingly, in our OSAHS patient sample, increasing
serum irisin level by 1 ng/mL fails to cause a significant
increase of the ESS score if serum BDNF levels are in
the lower range (e.g. below 280 ng/mL), indicating that
low irisin levels have a small, nonsignificant effect on
BDNF levels and consequently on ESS score. Con-
versely, changing serum irisin level by 1 ng/mL also
fails to exert a significant increase in the outcome
Table 1 Baseline characteristics of the study population (n = 69
patients)
Parameters
Age (years) 53.81 ± 10.72
Gender (female/ male) 18/51
Smoker (n/y) 57/12
RR systolic (mmHg) 140 (125–145)
RR diastolic (mmHg) 89.18 ± 9.52
Weight (kg) 94 (86.4–110)
Abdominal circumference 112 (106–123)
Neck circumference 44.10 ± 5.20
Height (m) 171.35 ± 7.63
BMI (kg/m2) 31.97 (28.77–37.03)
Irisin (ng/ml) 6.93 ± 8.40
BDNF (ng/ml) 368.80 ± 113.70
Glucose (mmol/L) 5.5 (5.2–6.2)
Cholesterol (mmol/L) 5.18 ± 1.05
Triglyceride (mmol/L) 1.5 (1.1–2.6)
CRP (normal/high) 54/12
Beck depression inventory score 6 (3–10)
Epworth score 10.04 ± 4.63
PSQI 5 (3–8)
AHI (1/h) 37.95 ± 23.97
Oxygen desaturation index (1/h) 25.4 (8.8–63.5)
Arousal index (1/h) 38.4 (20.6–55.4)
Central apnea index (1/h) 1.9 (0.7–4.6)
Obstructive apnea index (1/h) 12.1 (5.1–26.6)
Hypopnea index (1/h) 13.4 (8.8–20.3)
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Table 2 Comparison of the patients with respect to severity of obstructive sleep apnea hypopnea syndrome (OSAHS)
Parameters Mild to moderate OSA Severe OSA p
Age (years) 51.52 ± 11.14 55.47 ± 10.23 0.131
Gender (f/m) 11/18 7/33 0.056
Smoker (n/y) 24/5 33/7 0.978
Diabetes (n/y) 26/3 30/10 0.124
CAD (n/y) 25/4 35/5 0.875
CVD (n/y) 27/2 35/5 0.447
Metabolic syndrome (n/y) 3/21 5/34 0.970
RR systolic (mmHg) 135 (120–145) 141.25 (126.25–146.25) 0.300
RR diastolic (mmHg) 87.08 ± 8.23 90.44 ± 10.11 0.174
Arterial hypertension
(n/y)
12/16 4/36 0.002
Weight (kg) 91.2 (76.5–94.7) 100.85 (90.25–121.65) < 0.001
BMI (kg/m2) 30.07 (28.23–32.56) 35.51 (30.15–39.07) < 0.001
Abdominal circumference
(cm)
108 (99–113) 118.5 (109–126.5) < 0.001
Neck circumference
(cm)
40.96 ± 4.03 46.35 ± 4.80 < 0.001
Height (m) 169.93 ± 7.57 172.39 ± 7.59 0.189
Irisin (ng/ml) 6.91 ± 0.76 6.94 ± 0.90 0.886
BDNF (ng/ml) 359.12 ± 108.75 375.99 ± 118.12 0.549
IMT (mm) 0.61 ± 0.09 0.67 ± 0.09 0.015
Urea (mmol/L) 5.1 (4.1–6) 5.4 (4.3–6.6) 0.246
Creatinine (μmol/L) 69 (62–80) 80 (74–96) < 0.001
GOT (U/L) 18 (17–22) 21 (18–25) 0.044
GPT (U/L) 25 (19–32) 27 (20–39) 0.303
γGT (U/L) 29 (23–52) 38 (29–54) 0.154
CK (U/L) 109 (71–158) 120 (92–162) 0.297
LDH (U/L) 175 (160–200) 174 (159–201) 0.818
Glucose (mmol/L) 5.2 (5.1–5.7) 5.8 (5.2–6.7) 0.012
Insulin (mU/L) 13.2 (9.3–16.6) 16.2 (9.9–31.2) 0.133
HbA1C (%) 5.5 (5.2–5.9) 5.9 (5.5–6.5) 0.009
Cholesterol (mmol/L) 5.08 ± 1.10 5.25 ± 1.01 0.506
LDL-C (mmol/L) 3.25 ± 0.96 3.21 ± 1.09 0.885
HDL-C (mmol/L) 1.4 (1.2–1.6) 1.1 (0.90–1.2) < 0.001
Apo-A1 (g/L) 1.58 ± 0.23 1.35 ± 0.20 < 0.001
ApoB (g/L) 1.01 ± 0.25 1.11 ± 0.29 0.134
Lp(a) (mg/L) 390.52 ± 455.97 150.51 ± 205.51 0.005
TG (mmol/L) 1.1 (0.7–1.6) 1.8 (1.5–3.6) < 0.001
CRP (normal/high) 27/2 27/12 0.016
Beck score 5 (2.5–10.5) 6 (3–10) 0.608
Epworth score 8.21 ± 4.27 11.38 ± 4.48 0.004
PSQI 4 (3–8) 5 (4–7.5) 0.169
Oxygen desaturation index (1/h) 8 (6–16) 60.1 (29.9–84.4) < 0.001
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measure of interest at high serum BDNF levels (e.g.
above 470 ng/mL), implicating that a theoretical max-
imal effect (Emax) has been reached.
Similarly, increasing serum BDNF level by 1 ng/mL
only leads to a significant increase in the ESS score if
serum irisin levels are midrange e.g. fall between 6.1 ng/
mL and 8.1 ng/mL.
These latter findings further support our theoretical
presupposition that serum irisin is only one of several
factors influencing BDNF levels, hence it may be altered
independent of irisin (hence both parameters were in-
cluded in the multiple model, as BDNF levels are subject
to alter even at constant irisin levels).
Accordingly, BDNF expression is induced by metabolic
changes accompanying the transition from carbohydrate
and glucose utilization to fatty acids and ketones, a
metabolic switch characteristic of intermittent fasting and
exercise. Beta-hydroxybutyrate per se has been shown to
induce BDNF expression with respect to metabolic switch-
ing, a finding reproduced in cultured cerebral cortical
Table 2 Comparison of the patients with respect to severity of obstructive sleep apnea hypopnea syndrome (OSAHS) (Continued)
Parameters Mild to moderate OSA Severe OSA p
Arousal index (1/h) 26 (15.8–48.1) 48.1 (32.1–63.5) 0.002
Central apnea index (1/h) 1.1 (0.6–1.9) 3.3 (0.95–7.7) 0.002
Obstructive apnea index (1/h) 4.4 (3.0–7.0) 22.65 (15.65–41.1) < 0.001
Hypopnea index (1/h) 7.8 (5.6–12) 19.8 (14.1–26.8) < 0.001
Patients were grouped into mild to moderate (AHI at < 30/h, n = 29 patients) or severe OSAHS (AHI ≥ 30/h, n = 40 patients). Data are presented as mean ± SD or
median (interquartile range) unless otherwise stated. Differences between the two groups were considered significant at p < 0.05 (indicated in bold)
Table 3 Simple linear regression model for the Epworth Sleepiness Scale and serum irisin and BDNF levels
Parameter Coefficient (95% CI) p
Simple linear regression of irisin
Age in years −0.016 (−0.035; 0.002) 0.083
Gender (f/m) 0.087 (−0.385; 0.560) 0.713
Epworth score 0.043 (−0.000; 0.086) 0.051
(log)weight 1.019 (0.032; 2.006) 0.043
(log)triglyceride −0.317 (− 0.610; − 0.023) 0.035
Simple linear regression of BDNF
Age in years −1.986 (−4.525; 0.554) 0.123
Gender (f/m) −40.476 (−103.752; 22.799) 0.206
No. in household 23.274 (0.020; 46.528) 0.050
Simple linear regression of Epworth score
Age in years −0.020 (−0.125; 0.086) 0.711
Gender (f/m) 2.91 (0.460; 5.370) 0.021
No. in household 0.981 (0.035; 1.927) 0.042
Irisin (ng/mL) 1.321 (−0.007; 2.649) 0.051
AHI (1/h) 0.083 (0.040; 0.125) < 0.001
Oxygen desaturation index (1/h) 0.980 (0.050; 1.910) 0.039
(sqrt)Obstructive apnea index (1/h) 1.01 (0.49–1.55) < 0.001
(log)PSQI 2.427 (0.812; 4.042) 0.004
(sqrt)Beck 1.323 (0.398; 2.249) 0.006
(log)weight 8.477 (3.309; 13.645) 0.002
1/BMI −0.0252 (−0.045; 0.005) 0.015
Neck circumference (cm) 0.330 (0.128; 0.532) 0.002
(log)abdominal circumference 13.296 (5.168; 21.425) 0.002
Regression coefficient values are presented with their 95% confidence intervals (for the whole population of OSAHS patients: n = 69). The initial model for the
multiple regression analysis consisted of the significant parameters provided by the simple regression and the relevant a priori identified
parameters (statistical significance is indicated in bold)
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neurons under conditions of low glucose levels. Conversely,
beta-hydroxybutyrate was shown to inhibit histone deace-
tylases, a repressor of BDNF expression [59]. Further po-
tential sources of systemic BDNF level, independent of
irisin’s effects includes platelets [60], and various tissues of
the lung including the airway smooth muscle, bronchial
epithelium, smooth muscle cells and peripheral nerve
endings [61]. Hence, it is highly probable that the BDNF
levels may vary due to processes that are independent of
each other.
Worthy of notice is the finding that (log) PSQI was also
found to be a significant predictor in the final multiple
model especially if one considers the concept of two
process model of sleep [22]. Our results suggest that
poorer sleep quality (indicated by higher PSQI scores) re-
sults in more pronounced subjective daytime sleepiness.
Allowing a more speculative interpretation, this model
may intuitively posit that in the context of OSAHS alter-
ation of sleep-related processes should be interpreted in
terms of disrupted sleep homeostasis evolving due to
intermittent airway obstruction, consequent hypoxia, and
arousals and also via the alteration of the intertwining
circadian regulatory processes reflected by the complex
interaction between excessive daytime sleepiness and the
irisin/BDNF axis. This interpretation provides a sound
explanation for the phenomena of excessive daytime
sleepiness reported in CPAP-treated OSAHS patients, in
whom objective polysomnography-derived indices of
OSAHS were shown to be normalized, while daytime
sleepiness was preserved along with increased risk for
morbidities and mortality [28, 29]. Nevertheless, re-
cent advances in sleep research increasingly articulate
Table 4 Multiple linear regression model for the Epworth
Sleepiness Scale (ESS) and serum irisin and BDNF levels
Panel A Coefficient (95% CI) p
Age in years 0.02 (−0.091; 0.095) 0.970
Gender (f/m) 3.955 (1.761; 6.149) 0.001
Irisin (ng/mL) 1.530 (0.355; 2.705) 0.012
BDNF (ng/mL) 0.014 (0.005; 0.023) 0.002
(log) PSQI 2.972 (1.506; 4.437) < 0.001
Panel B Coefficient (95% CI) p
Age in years 0.001 (−0.092; 0.095) 0.974
Gender (f/m) 3.992 (1.768; 6.216) 0.001
Irisin (ng/mL) 0.973 (−2.898; 4.844) 0.006
BDNF (ng/mL) 0.003 (−0.069; 0.075)
Irisin-BDNF interaction term 0.002 (−0.009; 0.012)
(log) PSQI 2.965 (1.487; 4.442) < 0.001
Regression coefficient values are presented with their 95% confidence
intervals (CI). The initial model for the multiple linear regression analysis
consisted of the significant parameters provided by the simple linear
regression and the relevant a priori identified parameters (age,
gender) (statistical significance is indicated in bold)
Fig. 1 The model describing the linear relationship between Epworth Sleepiness Scale score and serum irisin and BDNF concentration in the
whole population (n = 69). The x-axis shows the serum irisin concentration (in μmol/L), while the y-axis denotes the ESS score. The blue and red
dots indicate the raw (i.e. original) values and fitted values obtained by multiple linear regression, respectively. The green and orange lines
indicate the curves fitted to the raw data and to data provided by multiple linear regression. Fitting was done by locally weighted scatterplot
smoothing (lowess)
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that circadian and homeostatic processes are mutually
influential, hence it is highly difficult to tease these
inferences apart [22, 62].
The molecular effectors of photic entrainment in the
SCN are via glutamate and pituitary adenylate cyclase-
activating polypeptide (PACAP) [10, 21]. Contribution of
BDNF, acting thru its cognate TrkB receptor to this
process has been described previously [21]. Dedicated
retinohypothalamic fibers containing blue light sensitive
photopigments terminate in the SCN where pre- and
postsynaptic TrkB receptors are expressed near BDNF-
expressing SCN cells. Hence the spatial relationship
permits modulating the synaptic interaction [21, 63].
Conversely, BDNF enhances the release of glutamate
and PACAP [21, 63, 64] and augments postsynaptic re-
sponse to glutamate via several mechanisms. It phos-
phorylates NMDA receptors, increasing the opening
probability of the channel in mice and rat [63, 65] and/
or increases the number of cell surface NMDA receptors
by inducing rapid cycling of the receptor [63].
The expression of BDNF within the SCN shows a
rhythmic pattern, elevating during subjective night from
the basal daytime level [66].During the day, transmission
of the light signal through the retinohypothalamic
Fig. 2 Association between Epworth Sleepiness Scale scores and serum irisin and BDNF levels. Panel A shows the observed values of ESS (axis z)
as a function of serum irisin and BDNF using interpolation within data coverage limits, while Panel B is a contour map of fitted values of ESS as
predicted by a multiple regression model with interaction between irisin and BDNF
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tract-SCN synapse is absent given the insufficiency of
basal BDNF level to permit excitatory neurotransmitter
release [21]. Accordingly, photic stimuli cannot entrain
the master clock, rendering the SCN insensitive to per-
turbations of light during the subjective day, while at
night the SCN responds to light by markedly shifting the
phase of this clock [21]. The fact that BDNF adminis-
tered into the SCN of rats permits phase shifts in
response to light during subjective day further corrobo-
rates BDNF’s gating function [67, 68]. Moreover, photic
entrainment is diminished in BDNF-deficient knockout
mice, and in rats if the tyrosine kinase inhibitor K252a is
infused into their SCN [21, 67]. Hence BDNF has a per-
missive effect in the SCN gating light’s ability to entrain
the master circadian clock in the SCN.
Prior work has suggested that BNDF is mandatory
for glutamate to induce the signal-transduction cas-
cade that mediates the light induced shift and thus
photic entrainment of the circadian system ensuring
that the organism’s internal circadian rhythm is
aligned with the geophysical day. Thus, it may be
concluded that BDNF assumes a critical role in photic
entrainment of the master clock by gating the circa-
dian system to light [21, 63], and irisin may modulate
Fig. 3 Scatter plots of serum BDNF versus serum irisin levels. Locations of model-estimated significant increase of ESS in response to a
unit increase in serum irisin (Panel a) and serum BDNF (Panel b) are indicated by filled circles. Symbol sizes are proportional to
effect magnitude
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this effect by influencing BDNF levels in the
hypothalamus.
A few clinical studies are available concerning the
change of neurotrophins in OSAHS. One early study
evaluated the expression profile of BDNF in adenotonsil-
lar tissue obtained from children undergoing adenoton-
sillectomy. Children were either suffering from OSAHS
or recurrent tonsillitis. No significant difference in the
mRNA levels was found between these two patient
groups [69]. A clinical trial including middle-aged
OSAHS patients (15 female and 24 male patients) and
controls (24 men) reported no significant difference in
average serum BDNF levels (11.22 ± 0.46 ng/mL vs.
11.17 ± 0.41 ng/mL for patients and controls, respect-
ively) [70]. The serum levels reported in the present
investigation are considerably higher, but fall within the
range reported by others. Studies including healthy indi-
viduals and other patient populations reported serum
BDNF levels spanning over four orders of magnitude,
ranging from 0.005 ng/ml to 280 ng/ml, [71–74] using
different ELISA kits. Our group has formerly reported
serum BDNF levels of 345.6 ng/mL (IQR 294.20–387.90
ng/mL) and 314.46 ± 118.68 ng/mL in cohorts of chronic
obstructive pulmonary disease patients [75] and bronchial
asthma [76], respectively. To the best of our knowledge
there are no reports concerning the serum level of irisin
in OSHAS patients. In one study evaluating the effects of
CPAP therapy in OSHAS patients, irisin levels were deter-
mined, however no absolute serum levels were reported,
only changes from baseline values, mean difference be-
tween groups and correlation coefficients were published
[77]. Previously our group has reported serum irisin levels
in the range of 7.22 ng/mL (IQR: 6.63–8.10 ng/mL) in
COPD and 7.87 ng/mL (IQR: 7.15–8.82 ng/mL) in asthma
patients. Others have reported irisin levels of 26.3 (IQR:
22.6–32.4) ng/ml, 53.7 (IQR: 46.7–62.8) ng/ml, 58.5
(42.8–78.9) ng/ml in smokers with and without COPD,
and in non-smoking individuals, respectively [78].
Choosing only the Epworth Sleepiness Scale to
characterize the possible alteration of circadian rhythm
could be regarded as a limitation of the current study. The
ESS is considered as a standard questionnaire appropriate
in the clinical setting to provide a subjective measure of
daytime sleepiness [41]. Furthermore, that objective meas-
ure of excessive daytime sleepiness was not obtained should
also be included among the limitations. It is acknowledged
that daytime sleepiness may be caused by several diseases
and conditions (e.g. poor sleep hygiene, primary hypersom-
nias, depression, obesity etc). These possible confounders
were handled by recruiting only OSAHS patients (note that
one of the diagnostic criteria for the clinical diagnosis of
OSAHS is excessive daytime sleepiness that is not due to
any other known causes e.g. primary hypersomnia), by ex-
cluding patients with certain co-morbidities (malignancies,
kidney disease, COPD and asthma) and by controlling for
parameters known to reflect conditions in which excessive
daytime sleepiness may be present (e.g. BMI, neck circum-
ference, Beck depression inventory score, included in the
initial model). In OSAHS, excessive daytime sleepiness is
generally considered to be the consequence of intermittent
nocturnal hypoxemia that leads to sleep fragmentation,
hence poorer sleep quality. To attest for the possible influ-
ence of reversible upper airway obstruction on daytime hy-
persomnolence, significant polysomnography derived
indices (AHI, oxygen desaturation index and obstructive
apnea index) were also included in the model as well as
(log) PSQI gauging perceived nocturnal sleep quality. Previ-
ous studies have shown a poor association between ESS
and PSQI as well as between PSQI, ESS and polysomnogra-
phy measures [79] to the extent that it was suggested that
these measures reflect distinct aspects of sleep. After con-
trolling for causes other than altered circadian rhythm, we
feel that ESS may be considered as an indicative parameter
reflective of altered circadian rhythm in our explorative
study. Nevertheless, characterization of the circadian
rhythm by obtaining serial measurements of either salivary
or serum melatonin or core body temperature could have
added value at the cost of extra inconvenience for the
patients and possibly have interfered with other measures
e.g. polysomnography. However, alteration of the circadian
rhythm in OSAHS has been established previously [37],
allowing the speculative notion that altered irisin/BDNF
axis may be causative for circadian misalignment in
OSAHS, and thus, it may be suggested that excessive day-
time sleepiness is a result of the deterioration of circadian
pacemaker process. This alternative mechanism could
account for the phenomenon of residual EDS as well as
the excess risk of cardiovascular and all-cause morbidity
and mortality in CPAP treated OSAHS patients. Measure-
ments from a single timepoint may be considered as
further limitation of the study, as serum BDNF levels are
themselves circadian [80]. Nevertheless, the current find-
ings suggest a putative relationship between the subjective
measure of excessive daytime sleepiness and the alteration
of the irisin/BDNF axis as reflected by the single measure-
ment. Furthermore, this finding may contribute to teasing
apart two parallel mechanisms underlying excessive day-
time sleepiness e.g. one stemming from the mechanical
obstruction of the airways and the other from the alter-
ation of the circadian regulation.
Nevertheless, the present work has several merits.
Presence of OSAHS was verified using overnight poly-
somnography conducted in an accredited sleep centre.
Stringent data analysis should also be considered a fur-
ther strength, as well as the fact that to the best of our
knowledge, this is the first-time absolute values of serum
irisin level are disclosed, and relatively little information
is available regarding serum BDNF levels in OSAHS.
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Conclusion
The current work proposes that the sleep related distur-
bances, sleep quality and excessive daytime sleepiness,
may be the outcome of distinct pathologies, e.g. mech-
anical obstruction, and deterioration of the circadian
rhythm, respectively. Furthermore, based on the finding
that excessive daytime sleepiness shows a strong associ-
ation with the alteration of the irisin-BDNF axis, we put
forward the speculative notion that these factors may be
causative in the evolution of circadian misalignment,
given the known involvement of BDNF in photic en-
trainment in the master clock of the SCN. Furthermore,
our results indirectly support the putative role of irisin
in altering the levels of BDNF at sites relevant regarding
circadian regulation.
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